Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...

U.K. biotech Ikarovec has teamed up with VectorBuilder to work on an eye disease gene therapy that could be administered in a ...

A study supported the ellipsoid zone loss as a meaningful biomarker that can be used to guide clinical trial design in ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye, and it marks the first of a three-part series on dry ...

The "Geographic Atrophy Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.The global ...

Both environmental factors (smoking, poor nutrition, etc.) and genetic factors contribute to the progression of AMD. In patients with bilateral AMD, only 54% were found to have symmetric disease, ...

People with macular degeneration and other forms of central vision loss can see details like text and faces with this device.

The AMD market is expected to grow at a CAGR of 10.2% over the course of the forecast period (2024–34), reaching $20.5bn ...

During the past few years, there have been tremendous advances in the treatment of several significant eye diseases, including macular degeneration, thyroid eye disease and eye infection. Macular ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...